Zacks Research Brokers Decrease Earnings Estimates for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at Zacks Research decreased their Q1 2025 earnings estimates for shares of Alnylam Pharmaceuticals in a research note issued on Wednesday, June 26th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of ($1.06) for the quarter, down from their prior forecast of ($0.95). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($3.92) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.58) EPS, Q1 2026 earnings at $0.31 EPS and FY2026 earnings at $2.58 EPS.

Several other analysts have also recently issued reports on the company. Stifel Nicolaus raised their target price on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research note on Thursday. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 25th. Canaccord Genuity Group reiterated a “buy” rating and set a $283.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, June 21st. UBS Group raised their price objective on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a report on Friday. Finally, SVB Leerink upped their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a report on Tuesday, June 25th. Eight research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $247.09.

Alnylam Pharmaceuticals Stock Down 1.6 %

Shares of ALNY opened at $243.00 on Monday. The stock has a market capitalization of $30.74 billion, a P/E ratio of -90.67 and a beta of 0.30. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $252.87. The firm has a fifty day simple moving average of $159.86 and a two-hundred day simple moving average of $164.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. During the same quarter in the previous year, the business earned ($1.40) earnings per share. Alnylam Pharmaceuticals’s revenue was up 54.8% compared to the same quarter last year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total transaction of $370,755.00. Following the completion of the sale, the chief financial officer now directly owns 28,892 shares of the company’s stock, valued at $6,674,052. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total value of $370,755.00. Following the completion of the transaction, the chief financial officer now directly owns 28,892 shares in the company, valued at $6,674,052. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the transaction, the executive vice president now owns 14,181 shares in the company, valued at approximately $3,275,669.19. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 67,357 shares of company stock valued at $13,436,711. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Alnylam Pharmaceuticals by 69.1% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock worth $36,203,000 after purchasing an additional 77,307 shares during the period. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after purchasing an additional 287,064 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its position in Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares during the period. Westpac Banking Corp lifted its stake in Alnylam Pharmaceuticals by 59.8% in the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 566 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Alnylam Pharmaceuticals by 630.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock valued at $5,007,000 after buying an additional 22,580 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.